Physician profile
William E Brown
NPI 1073715736
$6,190.04
in general payments reported to CMS, 2019-2025
26 companies · $625 in 2025
The $625 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,363 · 2020: $15.10 · 2021: $130 · 2022: $85.34 · 2023: $570 · 2024: $401 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.01 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $4,350.77 | 2019 | |
| Amgen INC. | $326.83 | 2024-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $235.62 | 2021-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $211.25 | 2021-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $186.08 | 2023-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $173.60 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $110.26 | 2021-2024 | Freestyle Libre 3 |
| Insightec,INC | $90.20 | 2023-2025 | Exablate |
| Sanofi Pasteur INC. | $74.85 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.48 | 2021-2024 | |
| Astellas Pharma US INC | $43.38 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $41.71 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $39.88 | 2023 | Nexletol, Contrave |
| Abbvie INC. | $30.14 | 2025 | |
| Averitas Pharma INC. | $27.31 | 2024 | Qutenza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $22.20 | 2023 | Keveyis |
| Inspire Medical Systems, INC. | $21.70 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $21.70 | 2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $17.54 | 2022 | |
| Philips North America LLC | $17.44 | 2024 | (Ck6) Holter |
| Dexcom, INC. | $17.44 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $15.18 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $15.10 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.11 | 2022 | |
| Mannkind Corporation | $13.77 | 2024 | |
| Pfizer INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.